ACTIVE_NOT_RECRUITING

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Description

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

Conditions

Obesity
Talk to us

Related Conditions:

Obesity

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Gardena

Velocity Clinical Research, Gardena, Gardena, California, United States, 90247

Irvine

Irvine Clinical Research, Irvine, California, United States, 92614

Los Angeles

Velocity Clinical Research, Westlake, Los Angeles, California, United States, 90057

North Hollywood

Velocity Clinical Research, North Hollywood, North Hollywood, California, United States, 91606

Santa Ana

Velocity Clinical Research, Santa Ana, Santa Ana, California, United States, 92704

Van Nuys

Velocity Clinical Research, Panorama City, Van Nuys, California, United States, 91405

Walnut Creek

Diablo Clinical Research, Inc., Walnut Creek, California, United States, 94598

Meridian

Solaris Clinical Research, Meridian, Idaho, United States, 83646

Marrero

Tandem Clinical Research, Marrero, Louisiana, United States, 70072

New Orleans

Velocity Clinical Research - New Orleans, New Orleans, Louisiana, United States, 70119

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m²
  • * Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention)
  • * Male or female contraceptive use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • * Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma
  • * Have a self-reported change (increase or decrease) in body weight \>5 kilogram (kg) within 3 months prior to screening
  • * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2
  • * Have acute or chronic hepatitis
  • * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-04